Biblio Discovery — Demo Discovery Service

103 hasil untuk "Steven Simoens"

Menampilkan 1–20 · 0,22 detik · RSS

  1. Artikel Jurnal

    How to assess the value of medicines?

    Steven Simoens

    Frontiers in Pharmacology, Vol. 1 · 2010 · Inggris · DOAJ Scopus

    This study aims to discuss approaches to assessing the value of medicines. Economic evaluation assesses value by means of the incremental cost-effectiveness ratio (ICER). Health is maximised by selecting medicines with increasing ICERs until the budget is exhausted. The budget size determines the…

  2. Artikel Jurnal

    Biosimilar medicines and cost-effectiveness

    Steven Simoens

    ClinicoEconomics and Outcomes Research, Vol. 2011 No. default · 2011 · Inggris · DOAJ Scopus

    Steven SimoensResearch Centre for Pharmaceutical Care and Pharmaco-economics, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, BelgiumAbstract: Given that biosimilars are agents that are similar but not identical to the reference biopharmaceutical, this study aims to…

  3. Artikel Jurnal Teks lengkap

    Assessment of methodological quality of economic evaluations in belgian drug reimbursement applications.

    Steven Simoens

    PLoS ONE, Vol. 8 No. 12 · 2013 · Inggris · DOAJ Scopus

    OBJECTIVES: This paper aims to assess the methodological quality of economic evaluations included in Belgian reimbursement applications for Class 1 drugs. MATERIALS AND METHODS: For 19 reimbursement applications submitted during 2011 and Spring 2012, a descriptive analysis assessed the…

    Juga tersedia di: PLOS

  4. Artikel Jurnal

    Societal economic burden of multiple sclerosis and cost-effectiveness of disease-modifying therapies

    Steven Simoens

    Frontiers in Neurology, Vol. 13 · 2022 · Inggris · DOAJ Scopus

    BackgroundIn an era of scarce resources, policy makers, neurologists and other stakeholders need to be aware of the economic burden of multiple sclerosis and the cost-effectiveness of disease-modifying therapies. The aim of this article is to provide a mini-review of these health economic facets of…

  5. Artikel Jurnal Teks lengkap

    Health Economics of Antibiotics

    Steven Simoens

    Pharmaceuticals, Vol. 3 No. 5 · 2010 · Inggris · DOAJ Scopus

    Antibiotics have made a significant contribution to improving patient health, but policy makers and health care payers are concerned about the costs of antibiotics in addition to their effectiveness. This paper aims to assess the value of antibiotics by examining incremental cost-utility ratios of…

  6. Artikel Jurnal Teks lengkap

    Generic Medicine Pricing Policies in Europe: Current Status and Impact

    Pieter Dylst; Steven Simoens

    Pharmaceuticals, Vol. 3 No. 3 · 2010 · Inggris · DOAJ Scopus

    Generic medicine pricing is an area of national responsibility of European Union countries. This article aims to present the current status and impact of generic medicine pricing policies in ambulatory care in Europe. The study conducts a literature review of policies relating to free-pricing…

  7. Artikel Jurnal Teks lengkap

    Emerging Insights into European Markets of Biologics, Including Biosimilars

    Steven Simoens; Isabelle Huys

    Pharmaceuticals, Vol. 15 No. 5 · 2022 · Inggris · DOAJ Scopus

    Biological medicinal products have revolutionised the treatment of many diseases, e [...]

  8. Artikel Jurnal

    R&D Costs of New Medicines: A Landscape Analysis

    Steven Simoens; Isabelle Huys

    Frontiers in Medicine, Vol. 8 · 2021 · Inggris · DOAJ Scopus

    Over the years, questions have been raised over R&D costs of new medicines. The aim of this study is to conduct a landscape review of the (drivers of) R&D costs of a new medicine derived from the peer-reviewed and grey literature. Included studies have drawn data either from confidential company…

  9. Artikel Jurnal

    Tendering and biosimilars: what role for value-added services?

    Steven Simoens; Raymond Cheung

    Journal of Market Access & Health Policy, Vol. 8 No. 1 · 2020 · Inggris · DOAJ Scopus

    Background: Access to biologic medicines (including biosimilars) across Europe is largely governed by a process of tendering conducted by health authorities. Over-reliance on treatment costs in awarding tenders has the potential to hinder competition and undermine the long-term sustainability of…

  10. Artikel Jurnal

    Guidance for Demonstrating the Societal Value of new Antibiotics

    Steven Simoens; Isabel Spriet

    Frontiers in Pharmacology, Vol. 11 · 2021 · Inggris · DOAJ Scopus

    Given that antibiotic use is associated with externalities, standard economic evaluation which considers costs and health gains accruing to patients under-values antibiotics. Informed by a scoping review, this discussion paper aims to identify the societal value elements of antibiotics and to…

  11. Artikel Jurnal

    Off-label use of orphan medicinal products: a Belgian qualitative study

    Marc Dooms; David Cassiman; Steven Simoens

    Orphanet Journal of Rare Diseases, Vol. 11 No. 1 · 2016 · Inggris · DOAJ Scopus

    Abstract Background Off-label use of (orphan) medicinal products for (rare) diseases is quite common but not underpinned by clinical studies to confirm efficacy and safety. No risk-analyses by regulatory agencies are carried out. The objective of this study was to map off-label use of orphan…

  12. Artikel Jurnal Teks lengkap

    Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study

    Steven Simoens; Arnold G. Vulto; Pieter Dylst

    Pharmaceuticals, Vol. 14 No. 5 · 2021 · Inggris · DOAJ Scopus

    This study aimed to compare drug costs and healthcare costs of a 1 year adjuvant course with intravenous biosimilar trastuzumab vs. subcutaneous reference trastuzumab in HER2-positive breast cancer from the Belgian hospital perspective. Our simulation is based on the methodology used by Tjalma and…

  13. Artikel Jurnal

    What role for real-world evidence in market access of biosimilars?

    Steven Simoens; Catherine M. Lockhart; Delphine Dioudonnat

    Frontiers in Pharmacology, Vol. 16 · 2025 · Inggris · DOAJ Scopus

    Experience with the use of biosimilars in real-life practice provides an excellent opportunity to collect real-world evidence aimed at addressing residual uncertainties about biosimilars. Hence, this Perspective aims to explore the role of real-world evidence on biosimilars by showcasing how…

  14. Artikel Jurnal

    Methodological Quality Assessment of Budget Impact Analyses for Orphan Drugs: A Systematic Review

    Khadidja Abdallah; Isabelle Huys; Kathleen Claes dkk.

    Frontiers in Pharmacology, Vol. 12 · 2021 · Inggris · DOAJ Scopus

    Objectives: This research aims to evaluate the methodological quality of budget impact analyses for orphan drugs and to provide suggestions for future analyses.Methods: Conference abstracts and peer-reviewed literature on budget impact analyses were collected through searches of Pubmed and Embase…

  15. Artikel Jurnal Teks lengkap

    Insights into European drug shortages: a survey of hospital pharmacists.

    Kim Pauwels; Steven Simoens; Minne Casteels dkk.

    PLoS ONE, Vol. 10 No. 3 · 2015 · Inggris · DOAJ Scopus

    Drug shortages are a complex and global phenomenon. When a drug cannot be delivered at the moment of patient demand, every stakeholder in the health care system is affected. The aim of this study was to investigate the characteristics, clinical impact, financial impact and management of drug…

    Juga tersedia di: PLOS

  16. Artikel Jurnal

    How to Value Orphan Drugs? A Review of European Value Assessment Frameworks

    Alessandra Blonda; Yvonne Denier; Isabelle Huys dkk.

    Frontiers in Pharmacology, Vol. 12 · 2021 · Inggris · DOAJ Scopus

    Background: Decision-makers have implemented a variety of value assessment frameworks (VAFs) for orphan drugs in European jurisdictions, which has contributed to variations in access for rare disease patients. This review provides an overview of the strengths and limitations of VAFs for the…

  17. Artikel Jurnal

    A Comparative Analysis of Pricing and Reimbursement of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Europe

    Khadidja Abdallah; Kris De Boeck; Marc Dooms dkk.

    Frontiers in Pharmacology, Vol. 12 · 2021 · Inggris · DOAJ Scopus

    Objectives: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators, Kalydeco® (ivacaftor), Orkambi® (lumacaftor/ivacaftor) and Symkevi® (tezacaftor/ivacaftor), have substantially improved patients’ lives yet significantly burden healthcare budgets. This analysis aims to compare…